DOCSLIB.ORG

Use of Anti-Glaucoma Drugs to Treat Visual Field Defects Associated with the Use of a Gabaergic Agent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Use of Anti-Glaucoma Drugs to Treat Visual Field Defects Associated with the Use of a Gabaergic Agent Europäisches Patentamt *EP001481668A1* (19) European Patent Office Office européen des brevets (11) EP 1 481 668 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/00, A61K 31/197, 01.12.2004 Bulletin 2004/49 A61K 38/18, A61P 25/08 (21) Application number: 04076366.6 (22) Date of filing: 06.05.2004 (84) Designated Contracting States: (72) Inventor: Ashby, Charles R. Jr. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Sound Beach, NY 11789 (US) HU IE IT LI LU MC NL PL PT RO SE SI SK TR Designated Extension States: (74) Representative: AL HR LT LV MK Winckels, Johannes Hubertus F. et al Vereenigde (30) Priority: 27.05.2003 US 446285 Nieuwe Parklaan 97 2587 BN Den Haag (NL) (71) Applicant: Brookhaven Science Associates Upton, New York 11973 (US) (54) Use of anti-glaucoma drugs to treat visual field defects associated with the use of a GABAergic agent (57) The invention provides a method for treating that improves retinal perfusion. Novel compositions visual field defects associated with the use of GABAer- containing a GABAergic drug and a drug that improves gic drugs in a mammal in need thereof. The method retinal perfusion are also provided. comprises administering an effective amount of a drug EP 1 481 668 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 481 668 A1 2 Description of GABAergic drugs in a mammal. The method includes administering to the mammal an effective amount of a BACKGROUND OF THE INVENTION drug that improves retinal perfusion. [0010] In another embodiment, the invention provides [0001] The invention relates to methods for treating 5 a composition containing a GABAergic drug, and an ef- visual field defects associated with the use of GABAer- fective amount of a drug that improves retinal perfusion. gic drugs, in mammals. [0011] In an alternate embodiment, a method for [0002] GABAergic drugs are known to increase treating visual field defects associated with use of a GABA levels in organs, such as the brain and eye. GABAergic drug in a mammal is provided that compris- These drugs are well known to be effective in the treat- 10 es administering an effective amount of erythropoietin. ment of conditions such as seizure disorders including, [0012] The invention also provides a composition for example, infantile spasms and epilepsy. comprising a GABAergic drug and an effective amount [0003] Recently, it has been reported that some of erythropoietin. GABAergic drugs such as, for example, gamma-vinyl GABA (GVG), are also effective for treating and prevent- 15 DETAILED DESCRIPTION OF THE INVENTION ing drug addiction. See U.S. Patent Nos. 6,057,368, 6,395,783, and 6,541,520 to Dewey et al., and pending [0013] The present invention is for novel composi- U.S. Patent Application Nos. 09/189,166; 09/362,592; tions and methods for treating visual field defects asso- and 09/853,548. ciated with the use of GABAergic drugs, in a mammal [0004] Typically, GVG functions by irreversibly inhib- 20 in need thereof. iting the GABA-degrading enzyme GABA transaminase [0014] By "treating" is meant administering to a mam- (GABA-T). The inhibition of GABA-T generally results in mal a therapeutically effective amount of a drug that im- an increase in GABA levels. Furthermore, it has been proves retinal perfusion so that the visual field defects shown that GVG-induced increases in GABA levels are at least partially and/or substantially completely al- cause a decrease in glutamate decarboxylase (GAD), a 25 leviated in the mammal. GABA synthesizing enzyme. [0015] In addition, treating means administering a [0005] It has been realized, however, that visual dis- therapeutically effective amount of a drug that improves turbances have been associated with the use of retinal perfusion so that the visual field defects are at GABAergic drugs. In particular, there have been reports least partially and/or substantially completely prevented that approximately 25-50% of patients treated with GVG 30 from occurring in the mammal. develop visual field defects (VFDs). Although the mech- [0016] Treating also means administering a therapeu- anism responsible for GVG-induced VFDs is unknown, tically effective amount of erythropoietin so that the vis- it is believed that the VFDs induced by GVG may be ual field defects are at least partially and/or substantially related to elevated levels of GABA within the retina. See, completely alleviated in the mammal. e.g. Comaish, et al., "The effects of vigabatrin on elec- 35 [0017] Treating also means administering a therapeu- trophysiology and visual field in epileptics: a controlled tically effective amount of erythropoietin so that the vis- study with a discussion of possible mechanisms." Doc. ual field defects are at least partially and/or substantially Opthalmol. 104:195-212 (2002). completely prevented from occurring in the mammal. [0006] One proposed method for treating or prevent- [0018] A "GABAergic drug" is any compound that po- ing VFDs associated with the use of GABAergic drugs, 40 tentiates the GABAergic system or increases gamma such as GVG, involves the administration of vitamin B6. amino butyric acid (GABA) levels in the central nervous See U.S. Application No. 10/389,578, filed March 17, system (CNS). According to the invention, the CNS in- 2003. It is believed that vitamin B6 mitigates the visual cludes the spinal cord, brain and midbrain regions. field defects by promoting GABA-T, which in turn de- GABA is a widespread inhibitory neurotransmitter in the grades any excess GABA. 45 CNS. GABA is made in the brain from the amino acid [0007] There exists a need for alternative approaches glutamate with the aid of vitamin B6. to preventing and/or treating VFDs associated with the [0019] GABAergic drugs include compounds that en- use of GABAegic drugs. hance the production or release of GABA in the CNS [0008] It is thus an object of the present invention to and/or increase GABAergic transmission. In addition, a provide compositions and methods for treating and/or 50 GABAergic drug is any compound that directly or indi- preventing VFDs associated with the use of GABAegic rectly augments or facilitates GABAergic neurotrans- drugs, such as GVG. mission in the CNS and/or the retina and/or the optic nerve. SUMMARY OF THE INVENTION [0020] These drugs include, but are not limited to, 55 gabapentin, valproic acid, progabide, gamma-hydroxy- [0009] These and other objectives have been met by butyric acid, fengabine, cetylGABA, topiramate, tiagab- the present invention. The invention provides a method ine, acamprosate (homo-calcium-acetyltaurine) or for treating visual field defects associated with the use pharmaceutically acceptable salts thereof, or enantiom- 2 3 EP 1 481 668 A1 4 ers or racemic mixtures thereof. ture in the methods of the instant invention and such [0021] A GABAergic drug is meant to include the advantages can be readily determined by those skilled pharmaceutically acceptable salts of the drug. As used in the art. herein, pharmaceutically acceptable salts include those [0028] For example, the enantiomer S(+)-gamma-vi- salt-forming acids and bases which do not substantially 5 nyl GABA is more effective at increasing endogenous increase the toxicity of the compound. Some examples intracellular GABA levels than the enantiomer R(-)-gam- of suitable salts include salts of mineral acids such as ma-vinyl GABA. hydrochloric, hydriodic, hydrobromic, phosphoric, met- [0029] Different enantiomers may be synthesized aphosphoric, nitric and sulfuric acids, as well as salts of from chiral starting materials, or the racemates may be organic acids such as tartaric, acetic, citric, malic, ben- 10 resolved by conventional procedures which are well zoic, glycollic, gluconic, gulonic, succinic, arylsulfonic, known in the art of chemistry such as chiral chromatog- e.g. p-toluenesulfonic acids, and the like. raphy, fractional crystallization of diastereomeric salts, [0022] The present invention embraces compositions and the like. which include prodrugs of GABA or drugs which contain [0030] According to the invention, "a mammal in need GABA as a moiety in its chemical structure. These pro- 15 thereof" is any mammal that has previously taken, is cur- drugs become pharmacologically active when metabol- rently taking, or will be taking, a GABAergic drug, for any ically, enzymatically or non-enzymatically biotrans- condition. formed or cleaved into GABA in the CNS. An example [0031] Such conditions include, for example, seizure of a prodrug of GABA is progabide, which upon crossing disorders and drug addiction. Exemplary seizure disor- the blood brain barrier, increases endogenous CNS 20 ders include, but are not limited to epilepsy and West GABA levels. syndrome (i.e. infantile spasms). [0023] A preferred GABAergic drug is gamma vinyl [0032] "Drug addiction" is defined as addiction to one GABA (GVG). GVG is represented by the compound or more drugs of abuse. Drugs of abuse include, but are 4-amino-hex-5-enoic acid, and is sold under the product not limited to, stimulants such as cocaine, ampheta- names Vigabatrin® and Sabril® by Hoechst-Marion 25 mine, pipradol, methylphenidate, nicotine and caffeine, Roussel. GVG is an irreversible inhibitor of the pyri- narcotics and pain medications such as morphine and doxal-phoshate dependent enzyme GABA transami- methadone, and central nervous system depressants nase (GABA-T) and is responsible for metabolizing such as barbiturates, chlordiazepoxide and ethanol. GABA to succinic semialdehyde. GVG is also known to [0033] According to the present invention, addiction inhibit other transaminases, such as, for example, 30 to a combination of one or more drugs of abuse is also alanine aminotransferase and ornithine aminotrans- a condition that is treated by administering a GABAergic ferase. drug. [0024] Not being bound by theory, it is believed that [0034] A "mammal" suitable for the methods of the GVG's action results in an accumulation of GABA within present invention is any mammal, including a human, the nerve terminal, and ultimately, an increase in syn- 35 domestic animal (e.g.
Load more

Recommended publications
  • ANNNNNNNNNNNNNNNNNNNN 100A 006 Left Eye Input Right Eye Input
    US 20190175049A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0175049 A1 Welling ( 43 ) Pub . Date : Jun . 13 , 2019 ( 54 ) TECHNIQUES FOR ANALYZING (52 ) U . S . CI. NON -VERBAL MARKERS OF CONDITIONS CPC . .. A61B 5 /04842 (2013 . 01 ) ; A61B 5 / 7289 USING ELECTROPHYSIOLOGICAL DATA (2013 . 01) ; A61B 5 /0478 ( 2013 .01 ) ; A61B 5 /7225 ( 2013. 01 ) ; G06N 20 / 10 (2019 .01 ) (71 ) Applicant: Massachusetts Institute of Technology , Cambridge , MA (US ) ( 57 ) ABSTRACT (72 ) Inventor : Caroline Welling, Hanover, NH (US ) Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry . Sensed ( 21 ) Appl. No. : 16 / 206, 639 electrical activity of a subject' s brain is received over a time period while the subject is exposed to a visual stimulus. The ( 22 ) Filed : Nov. 30 , 2018 sensed electrical activity comprises a first frequency band Related U . S . Application Data associated with a first frequency of a first image presented to the subject ' s left eye , a second frequency band associated (60 ) Provisional application No .62 / 593 , 535, filed on Dec . with a second frequency of a second image presented to the 1 , 2017 subject ' s right eye . A set of events in the time period is determined based on the frequency bands, wherein an event Publication Classification is associated with a change from a previous perceptual event (51 ) Int. Ci. to a new perceptual event. A metric for the subject is A61B 5 /0484 ( 2006 .01 ) determined based on the set of events . The metric is ana A61B 5 /00 ( 2006 .01 ) lyzed to determine whether the subject exhibits signs asso GO6N 20 / 10 (2006 .01 ) ciated with a condition that is associated with binocular A61B 5 /0478 ( 2006 .01 ) rivalry .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Calcium Channel Blocker As a Drug Candidate for the Treatment of Generalised Epilepsies
    UNIVERSITAT DE BARCELONA Faculty of Pharmacy and Food Sciences Calcium channel blocker as a drug candidate for the treatment of generalised epilepsies Final degree project Author: Janire Sanz Sevilla Bachelor's degree in Pharmacy Primary field: Organic Chemistry, Pharmacology and Therapeutics Secondary field: Physiology, Pathophysiology and Molecular Biology March 2019 This work is licensed under a Creative Commons license ABBREVIATIONS AED antiepileptic drug AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ANNA-1 antineuronal nuclear antibody 1 BBB blood-brain barrier Bn benzyl BnBr benzyl bromide BnNCO benzyl isocyanate Boc tert-butoxycarbonyl Bu4NBr tetrabutylammonium bromide Ca+2 calcium ion CACNA1 calcium channel voltage-dependent gene cAMP cyclic adenosine monophosphate CCB calcium channel blocker cGMP cyclic guanosine monophosphate CH3CN acetonitrile Cl- chlorine ion Cmax maximum concentration CMV cytomegalovirus CTScan computed axial tomography DCM dichloromethane DIPEA N,N-diisopropylethylamine DMF dimethylformamide DMPK drug metabolism and pharmacokinetics DNET dysembryoplastic neuroepithelial tumours EEG electroencephalogram EPSP excitatory post-synaptic potential FDA food and drug administration Fe iron FLIPR fluorescence imaging plate reader fMRI functional magnetic resonance imaging GABA γ-amino-α-hydroxybutyric acid GAD65 glutamic acid decarboxylase 65 GAERS generalised absence epilepsy rat of Strasbourg GluR5 kainate receptor GTC generalised tonic-clonic H+ hydrogen ion H2 hydrogen H2O dihydrogen dioxide (water)
    [Show full text]
  • A Comparative Study of Progabide, Valproate, and Epilepsy
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.49.11.1251 on 1 November 1986. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:1251-1257 A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy P CRAWFORD, D CHADWICK From the Department ofNeurology, Walton Hospital, Liverpool, UK SUMMARY A three way single blind cross-over comparison of progabide, valproate and placebo, as adjunctive therapy, was undertaken in 64 patients with therapy-resistant partial and generalised seizures. The study was not completed because of the incidence of elevated hepatic enzymes on progabide. Analysis of efficacy showed progabide to be inferior to valproate against all seizure types, particularly against tonic-clonic seizures. Valproate was superior to placebo against all seizure types, partial and tonic-clonic seizures. Progabide did not differ significantly from placebo in any instance. In addition progabide caused elevation of hepatic enzymes which was symptomatic in one case, and was associated with an interaction with phenytoin symptoms which resulted in of guest. Protected by copyright. intoxication in some cases. Progabide is a pro-drug and a GABA agonist which treatment limb was of six months with a two week washout possesses anticonvulsant properties in a variety of and cross-over period between treatment phases. Patients experimental models of seizures and epilepsy.' with severe, partial or generalised epilepsies were eligible for Whether it possesses antiepileptic properties in man is admission to the study as long as they had a definite history controversial. A number of double blind of epilepsy confirmed by observation and EEG recording studies and suffered a minimum of one seizure per month during the against placebo have been reported, some of which six months prior to entry into the study.
    [Show full text]
  • Late Shri Vishnu Waman Thakur Charitable Trust`S VIVA INSTITUTE of PHARMACY At: Shirgaon, Veer Sawarkar Road, Virar (E), Taluka: Vasai, Dist
    Late Shri Vishnu Waman Thakur Charitable Trust`s VIVA INSTITUTE OF PHARMACY At: Shirgaon, Veer Sawarkar Road, Virar (E), Taluka: Vasai, Dist. Palghar-401305, Maharashtra. FINAL YEAR UNIVERSITY EXAMINATION 2019-2020 Final Year B.Pharm. Semester VIII SUBJECT-BPH_C_801_T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK Q. 1 Which is the correct IUPAC name for the following structure? A] 5-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine B] 7-chloro-2-(methylamino)-5-pyridinyl-3H-1,4-benzodiazepine-4-oxide C] 7-chloro-2-(ethylamino)-5-phenyl-3H-1,5-benzodiazepine D] 7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide Q. 2 Which of the following is long acting sedative hypnotic? A] Diazepam B] Alprazolam C] Temazepam D] Imipramine Q. 3 Name of oxide derivative used as sedative hypnotic is A] Diazepam B] Chlordiazepoxide C] Nitazepam D] Ramelteon Late Shri Vishnu Waman Thakur Charitable Trust`s VIVA INSTITUTE OF PHARMACY At: Shirgaon, Veer Sawarkar Road, Virar (E), Taluka: Vasai, Dist. Palghar-401305, Maharashtra. Q. 4 With respect to the following general structure which is the correct statement ? A] X must be electropositive substituent for optimum activity B] X must be aromatic ring for optimum activity C] X must be electronegative substituent for optimum activity D] X must be H for optimum activity Q. 5 Which is the incorrect statement with respect to structure given in Q. 4 A] Ring C is ortho substituted with electron withdrawing group for optimum activity B] Ring C when para substituted increases activity C] Ring C is diortho substituted with electron withdrawing group for optimum activity D] Ring C when para substituted decreases activity Q.
    [Show full text]
  • Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK
    FINAL YEAR UNIVERSITY EXAMINATION 2019-2020 Final Year B.Pharm. Semester VIII SUBJECT-BPH_C_801_T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK SET-I Q. 1 Which is the correct IUPAC name for the following structure? A] 5-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine B] 7-chloro-2-(methylamino)-5-pyridinyl-3H-1,4-benzodiazepine-4-oxide C] 7-chloro-2-(ethylamino)-5-phenyl-3H-1,5-benzodiazepine D] 7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide Q. 2 Which of the following is long acting sedative hypnotic? A] Diazepam B] Alprazolam C] Temazepam D] Imipramine Q. 3 Name of oxide derivative used as sedative hypnotic is A] Diazepam B] Chlordiazepoxide C]Nitazepam D] Ramelteon Q. 4 With respect to the following general structure which is the correctstatement ? A] X must be electropositive substituent for optimum activity B] X must be aromatic ring for optimum activity C] X must be electronegative substituent for optimum activity D] X must be H for optimum activity Q. 5 Which is the incorrect statement with respect to structure given in Q. 4 A] Ring C is ortho substituted with electron withdrawing group for optimum activity B] Ring C when para substituted increases activity C] Ring C is diortho substituted with electron withdrawing group for optimum activity D] Ring C when para substituted decreases activity Q. 6 What is the starting material for synthesis of Piroxicam (structure given below) A] B] C] D] Q. 7 Which one of the following is Cytokine inhibitor? A] Abatacept B] Fluoxetine C] Propranolol D]Aldosterone Q.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]